Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Down 20.1% in June

Altamira Therapeutics Ltd. (NASDAQ:CYTO) was the target of a significant drop in short interest during the month of June. As of June 15th, there was short interest totalling 102,900 shares, a drop of 20.1% from the May 31st total of 128,800 shares. Based on an average daily trading volume, of 1,930,000 shares, the short-interest ratio is presently 0.1 days. Approximately 4.6% of the shares of the company are short sold.

Institutional Investors Weigh In On Altamira Therapeutics

An institutional investor recently bought a new position in Altamira Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Altamira Therapeutics Ltd. (NASDAQ:CYTO) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 829,000 shares of the company’s stock, valued at approximately $203,000. Armistice Capital LLC owned about 11.86% of Altamira Therapeutics as of its most recent SEC filing. 1.91% of the stock is currently owned by hedge funds and other institutional investors.

Altamira Therapeutics Price Performance

Shares of NASDAQ CYTO remained flat at $1.11 during midday trading on Friday. 70,962 shares of the stock traded hands, compared to its average volume of 64,611. Altamira Therapeutics has a one year low of $1.05 and a one year high of $17.20. The company’s 50 day simple moving average is $1.45 and its two-hundred day simple moving average is $1.96.

Altamira Therapeutics Company Profile

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.